Veradigm Inc
OTC:MDRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (19.2), the stock would be worth $-7.53 (275% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -11 | $4.3 |
0%
|
| Industry Average | 19.2 | $-7.53 |
-275%
|
| Country Average | 19.6 | $-7.67 |
-278%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$209.9m
|
/ |
Jan 2023
$-19.1m
|
= |
|
|
$209.9m
|
/ |
Dec 2023
$82.7m
|
= |
|
|
$209.9m
|
/ |
Dec 2024
$47.2m
|
= |
|
|
$209.9m
|
/ |
Dec 2025
$39.6m
|
= |
|
|
$209.9m
|
/ |
Dec 2027
$141.8m
|
= |
|
|
$209.9m
|
/ |
Dec 2028
$86.8m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Veradigm Inc
OTC:MDRX
|
456.1m USD | -11 | -5.3 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 43.2 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
26.8B USD | 21.2 | 29.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.7B AUD | 77.9 | 62.9 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 12.3 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.8B SEK | -133.5 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.9B USD | 23.3 | 42.3 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 15.7 | 18.8 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 4 290.1 | -328 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19B CNY | -120.1 | -61.5 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.8B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Veradigm Inc
Glance View
Veradigm Inc., formerly known as Allscripts Healthcare Solutions, has carved out a distinct niche within the healthcare technology landscape. The company focuses on the dynamic intersection of technology and healthcare, developing an array of solutions aimed at enhancing healthcare delivery and efficiency. Essentially, Veradigm equips medical professionals with tools for electronic health records, practice management, and remote patient monitoring. By leveraging sophisticated information systems, Veradigm helps streamline operations in doctor's offices, hospitals, and healthcare organizations, making it easier for healthcare providers to deliver efficient and effective services. Their products are designed not only to improve clinical workflows but also to enhance patient engagement, ultimately leading to better health outcomes. The revenue model of Veradigm hinges largely on contractual agreements and subscriptions for its software solutions. By offering a range of cloud-based services, the company ensures a steady flow of recurrent income while reducing the need for expensive on-site installations, thus delivering value to both large hospital systems and smaller, private practices. Additionally, Veradigm has diversified its revenue streams through collaborations with pharmaceutical companies, providing data insights and support for research and marketing initiatives. With a persistent focus on innovation and adaptability, Veradigm not only strengthens its foundational business in healthcare IT but also taps into new opportunities within the emerging landscape of digital health and data analytics.
